AstraZeneca, University of Texas MD Anderson Cancer Center deal

AstraZeneca partnered with MD Anderson to evaluate undisclosed compounds from AZ’s pipeline in clinical and clinically related studies in ovarian and gynecologic cancers. Under the three-year deal, AZ is providing undisclosed funding, with at least 25% of the funding designated for non-clinical, clinically related research studies, such as non-interventional cost-effectiveness and epidemiological studies. A joint steering committee will be comprised of senior AZ executives and clinicians/scientists at MD Anderson. AZ retains commercial rights, and MD Anderson will have the right to use the data for internal, non-commercial research and academic purposes and to publish data in accordance with the deal. ...